LONA

#4478
LeonaBio, Inc. Common Stock
9.48 USD
+4.52%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
9.48
9.48
Rango anual
4.22
14.19
Cambio diario
+4.52%
Variación mensual
+23.60%
Variación en los últimos 6 meses
+40.65%
Cambio anual
+40.65%
Cierres anteriores
9.07
Abrir
9.48
Bid
Ask
Mínimo
9.48
High
9.48
Volumen
1
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

LeonaBio Inc

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.